Novo Nordisk Announces Entry of Obesity Treatment Blood Sugar Control Drug 'Amycretin' Into Phase 3 Clinical Trials

Novo Nordisk announced today that it has decided to advance the subcutaneous injection and oral candidates of 'Amycretin,' developed for obesity management, into Phase 3 clinical trials.

This decision was made based on feedback exchanged with regulatory authorities during the final stage of Phase 2 trials.

In other words, the regulatory agencies gave positive feedback regarding the progression to Phase 3 trials.

Martin Lange, Vice President of Novo Nordisk’s Development Department, expressed high expectations for the Amycretin molecule and called this Phase 3 advancement a significant milestone.

The company plans to initiate the Phase 3 program in the first quarter of 2026, targeting overweight and obese adults.

Clinical trials typically represent a stage in the new drug development process, with Phase 3 focusing on verifying efficacy and safety in a larger population.

Especially for obesity treatments, demand is high in the market, so if successful, this could be a major growth driver for Novo Nordisk.

It is also positive that both subcutaneous injections and oral medications are under development, which means improved convenience for patients.

Although there is no specific data yet on stock market reactions, news of entering Phase 3 is generally regarded positively in the pharmaceutical industry.

Amycretin belongs to the 'amylin' class of new drugs and is said to have a mechanism that helps regulate blood sugar and body weight—in simple terms, it aids weight loss by controlling blood sugar and suppressing appetite.

Personally, with the increasing importance and social interest in obesity treatments, I believe the successful development of this drug by Novo Nordisk could have a significant impact.

Considering that over half of Americans are overweight or obese, this could also help reduce medical expenses and improve quality of life.

This promising drug development news makes it necessary to closely monitor the progress of Phase 3 trials moving forward.